Published in J Cancer Res Clin Oncol on March 03, 2017
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 9.90
Oligometastases. J Clin Oncol (1995) 4.95
Liver resection for colorectal metastases. J Clin Oncol (1997) 4.88
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
Solitary colorectal liver metastasis: resection determines outcome. Arch Surg (2006) 2.06
Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys (2011) 2.03
Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol (2006) 1.72
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68
Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol (2006) 1.56
Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. Int J Radiat Oncol Biol Phys (2015) 1.52
Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer. J Thorac Oncol (2014) 1.51
The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol (2007) 1.49
Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol (2011) 1.48
Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2008) 1.47
Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin (2009) 1.28
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys (2009) 1.24
Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg (2007) 1.23
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.20
Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis. Am J Clin Oncol (2010) 1.06
Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg (2008) 1.03
Predictive factors for local recurrence of resected colorectal lung metastases. Ann Thorac Surg (2005) 0.97
Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys (2016) 0.90
The usefulness of stereotactic radiosurgery for radioresistant brain metastases. J Korean Neurosurg Soc (2013) 0.86
Stereotactic body radiation therapy for oligometastases. Discov Med (2010) 0.83
Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J Neurooncol (2015) 0.81
Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys (2015) 0.80
Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. Chest (1999) 0.80
Gamma Knife stereotactic radiosurgery for intracranial metastases from conventionally radioresistant primary cancers: outcome analysis of survival and control of brain disease. South Med J (2009) 0.80